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Introduction: In early stage non-small cell lung cancer (NSCLC),
presence of lymphatic micrometastases and isolated tumor cells,
primarily detected by immunohistochemistry, is suggested to be
a prognostic factor. However, there is no consensus whether
immunohistochemistry should be used routinely in lymph node
assessment.
The goal of our study was to determine whether recurrent
disease is associated with the presence of lymphatic micrometasta-
ses and/or isolated tumor cells, at the time of the lung resection.
Methods: We retrospectively analyzed the prevalence of lymphatic
micrometastases and/or isolated tumor cells in two groups of pa-
tients, who underwent a curative resection for early stage NSCLC.
Group I had a follow-up of 5 years without recurrent disease. Group
II consisted of a matched group of patients with recurrent disease.
Patients were originally classified as having negative mediastinal
lymph nodes.
All lymph nodes obtained by mediastinoscopy and thoracotomy
were re-examined by serial sectioning and immunohistochemistry.
Results: Micrometastases and/or isolated tumor cells were found in
one of 16 patients in group I, which was significantly different from
six of 16 patients in group II. (Fisher exact test, 4.6; p, 0.04; risk
ratio, 2.4).
Serial sectioning and immunohistochemistry did not change
N-stage for the single patient in group I, in contrast to all six patients
in group II.
Conclusion: Presence of lymphatic micrometastases and/or isolated
tumor cells is associated with distant recurrence in patients with
early stage NSCLC. We recommend the routine use of serial
sectioning and immunohistochemistry in lymph node assessment to
improve the accuracy of staging.
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In patients with non-small cell lung cancer (NSCLC), re-gional lymph node involvement is a major prognostic fac-
tor, and in the absence of distant metastases, assessment is
essential to determine the appropriate therapy. In clinical
practice, nodal assessment is based on computed tomography
scan and fluorodeoxyglucose-positron emission tomography
(FDG-PET), to provide anatomic and metabolic information,
respectively. Histologic proof of lymph node involvement is
preoperatively obtained by endoscopic needle biopsy and/or
mediastinoscopy. Moreover, in case of a lung resection, both
intrapulmonary and mediastinal lymph nodes are recom-
mended to be resected, enabling classification in a pathologic
stage of the disease.1
However, despite an intended curative treatment, 25 to
50% of patients with early stage lung cancer develop a
recurrence during follow-up,2 thus, suggesting occult disease
and inaccurate staging. This occult disease may be repre-
sented by lymphatic spread of isolated tumor cells and mi-
crometastases, defined as small clusters of tumor cells of 0.2
mm or less and clusters of 0.2 mm to 2 mm in diameter,
respectively.3
Several reports4–6 have addressed the prognostic sig-
nificance of lymphatic isolated tumor cells and micrometas-
tases, but controversy remains about their clinical impact.7–11
If clinically important, detection of isolated tumor cells and
micrometastases not only affects staging and therapy, but
may also act on the position of invasive diagnostics in the
workup of patients with lung cancer, because there is a
different yield of lymphatic tissue obtained by different
diagnostic tools.
The goal of this study was to determine whether recur-
rent disease was associated with the presence of lymphatic
isolated tumor cells and/or micrometastases at the time of the
lung resection.
PATIENTS AND METHODS
Design
To determine the clinical value of lymphatic isolated
tumor cells and micrometastases, we analyzed their preva-
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lence in two groups of patients who had undergone a com-
plete resection for early stage NSCLC in a retrospective case
control study.
All patients were originally classified as having nega-
tive mediastinal lymph nodes, both after clinical workup and
based on the final pathology report after surgery.
Group I consisted of patients without any sign of
recurrence during a follow-up of at least 5 years after the
operation. This group was matched with a second group of
patients, who did develop recurrent disease during follow-up,
despite their complete resection (group II).
Patients were matched for age, sex, performance status,
weight loss, histology, type of resection, and pathologic
tumor, node, metastasis stage.2 Patient characteristics are
presented in Table 1.
Patients were included in this study retrospectively
from a surgical data base. Follow-up information was col-
lected from the patient’s medical files of the referring pul-
monologists.
Surgery
Surgical treatment consisted of (at least) a lobectomy
with en bloc resection of the lobar lymph nodes. Dissection of
interlobar and hilar lymph nodes was routinely performed, as
well as a lobe specific mediastinal lymph node dissection.1
On average, 4.5 mediastinal lymph node stations (range 3–6)
per patient were dissected. Surgery was supposed to be
complete if the bronchial, vascular, and pleural resection
margins were free, and there was no involvement of the
mediastinal lymph nodes.
None of the patients in this study received induction-
nor adjuvant chemo- or radiotherapy.
Pathology
Of the patients included in this study, first a re-exam-
ination of the original hematoxylin and eosin stained slides of
both the primary tumor, bronchial resection margin, and
lymph nodes obtained by mediastinoscopy and thoracotomy
was carried out to confirm histology and pathologic stage.
Next, all formalin-fixed and paraffin-embedded
lymph nodes were once more sectioned at two levels of 50-
and 85-m deep. At each level, a 5-m tissue section was
taken and hematoxylin-eosin stained for pathologic assess-
ment. Second, two 5-m tissue sections at levels of 60- and
65-m deep were taken and immunohistochemically stained
with the keratin monoclonal antibodies Cytokeratin pan AE1/
AE3 (1:200; Neomarkers, Fremont, CA) and Cytokeratin
8/Cam5.2 (1:20; Becton & Dickinson, Franklin Lakes, NJ)
using the standard avidin-biotin-complex technique.12 After
the first incubation with the keratin antibodies, a second
incubation was performed with horse-antimouse biotinylated
antibody (Vector laboratories, Burlingame, CA). Subse-
quently, all attached antibodies were developed using the
avidin-biotin-peroxidase method Vectastain, ABC-kit Elite
standard (1:100, Vector Laboratories). Finally, all tissue sec-
tions were shortly counterstained with hematoxylin. Appro-
priate negative and positive controls were runned parallel
with the staining procedures.
Assessment of these additional slides after immunohis-
tochemistry and reclassification of nodal status was done by
a pathologist unaware of a recurrence during follow-up.
Statistics
Based on previous reports,4–9,11 we hypothesized a
prevalence of isolated tumor cells and/or micrometastases in
our patients of 25% and intended to demonstrate a different
prevalence between the group with and without recurrent
disease of at least 35%. The  (error probability) was set to
0.05. A power analysis (with a z-test proportion method for
differences between two proportions) revealed that the study
population had to consist of two groups of 16 patients each.
A Pearson 2 test (Fisher exact test) was used to demonstrate
the difference between both groups. A one-tailed significance
level of 0.05 was considered significant. Statistical analyses
were performed using SPSS software, version17.0 (SPSS,
Inc., Chicago, IL).
RESULTS
Pathologic Assessment
In addition to the lobar and interlobar lymph nodes of
each patient, 145 mediastinal lymph node stations, with an
average of 2.4 lymph nodes per station (range 1–7), in 32
patients were available for re-examination.
Reassessment of the original hematoxylin and eosin
stained slides, to confirm the histologic diagnosis and stage,
TABLE 1. Clinical and Pathologic Characteristics of
Patients With and Without Recurrence After 5-yr Follow-Up
(n  32)
No Recurrence,
Group I (n  16)
Recurrence,
Group II (n  16)
Age
Mean (range) 64 (54–77) 62 (38–70)
Sex
Male 15 13
Female 1 3
ECOG performance status
0 1 1
1 15 15
Weight lossa
Yes 3 4
No 13 12
Histology
Squamous cell carcinoma 13 12
Adenocarcinoma 1 4
Large cell carcinoma 2 —
Type of resection
Lobectomy 7 6
Pneumonectomy 9 10
Stage (pTNM)
T1N0 2 1
T2N0 9 9
T2N1 5 6
a More than 5% in 6 mo before initial diagnosis.
ECOG, Eastern Cooperative Oncology Group; pTNM, pathologic tumor, node,
metastasis.
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revealed an overt hilar lymph node metastasis in one patient
that was missed at first examination, but no mediastinal
lymph node metastases were detected.
After subsequent immunohistochemical analysis, addi-
tional lymph node metastases were identified in seven of 32
patiens (22%).
In group I, consisting of patients without recurrent
disease, micrometastases were detected in hilar lymph
nodes in only one patient (6%). This patient had already
been staged pT2N1, based on direct tumor invasion of an
adjacent lymph node.
In group II, patients with recurrent disease, isolated
tumor cells and/or micrometastases were identified in six
patients (38%), which was significantly different from the
single patient in group I (Fisher exact test, 4.6; p, 0.04; risk
ratio, 2.4).
Influence on Stage
For the single patient in group I, the pathologic stage
remained unchanged. In group II, initial staging was pT1N0
in 1 patient, pT2N0 in nine patients, and pT2N1 in six
patients. In three of these nine patients staged pT2N0, iso-
lated tumor cells and/or micrometastases were identified
(33%), in two patients in both N1 and N2 lymph nodes, and
in one patient in hilar lymph nodes only.
In three of the six patients, initially staged pT2N1
positive mediastinal lymph nodes were identified (50%).
Because of the serial sectioning and immunohisto-
chemistry, five of six patients from group II were upstaged:
from stage Ib to stage IIIa in two patients, from stage Ib to IIb
in one patient, and from stage IIb to IIIa in two patients. In the
remaining patient from group II, initially staged IIb, the
N-stage changed from N1 to N1 (i), because only isolated
tumor cells were found in mediastinal lymph nodes, but no
micrometastases were found.
The yield of pathologic re-examination and stage mi-
gration observed by serial sectioning and immunohistochem-
istry are shown in Table 2.
Time to Recurrence
For the patients in group II, the time interval from the
operation until the first sign of a metastasis ranged from three
to 48 months, with a mean interval of 12.8 months. The
interval tended to be shorter for patients with micrometasta-
ses (mean 8.6 months, range 5–16) than for patients without
micrometastases (mean 15.4 months, range 3–48), but there
was no significant difference.
In all patients with micrometastases, the first clinical
recurrence was at a distant site.
DISCUSSION
Our study shows that the prevalence of lymphatic
micrometastases and isolated tumor cells is significantly
increased in patients who underwent a complete resection
for NSCLC and developed distant recurrent disease during
follow-up, compared with a matched group of patients
without recurrent disease. This demonstrates that minimal
lymph node involvement represents tumor dissemination
with a significant clinical impact, that is, prediction of
tumor recurrence.
Although micrometastases can be detected by using
hematoxylin and eosin staining only, detection may be im-
proved by serial sectioning, immunohistochemistry, or mo-
lecular techniques as (reverse transcription-) polymerase
chain reaction. Moreover, these methods are essential to
detect isolated tumor cells, but thus far none of these methods
is routinely used in lymph node assessment in NSCLC. We
retrospectively demonstrated the presence of lymphatic mi-
crometastases and isolated tumor cells by pathologic re-
examination with serial sectioning and immunohistochemis-
try at two levels.
The overall prevalence of micrometastases and isolated
tumor cells in our patients of 22% is within the range of
expected and comparable to other studies, with a prevalence
ranging from 16 to 74%.4–9,11 Obviously, the prevalence may
be influenced by the study design. By definition half of our
study population had a favorable outcome, with an expected
limited prevalence of occult disease.
Because of the serial sectioning and immunohisto-
chemistry, five of 16 patients with recurrent disease seemed
to have mediastinal dissemination. Whether their prognosis is
the same as for patients with overt N2 disease cannot be
answered from this study. Minimal N2 disease may represent
a favorable subgroup in patients with mediastinal lymph node
involvement,13 on the other hand, in a recent study by Riquet
TABLE 2. Stage Migration of Seven Patients with Lymph Node Involvement Detected by Serial Sectioning and
Immunohistochemistry
Patient (Study nr.) Histology Original p Stage Yield of Re-Examination p Stage After IHC
Group I: no recurrence
26 Squamous cell T2N1 Micrometastases N1 Unchanged
Group II: with recurrence
6 Squamous cell T2N0 Micrometastases N1  N2 T2N2
9 Adeno T2N1 Micrometastases  ITCs N2 T2N2
10 Adeno T2N1 ITCs N2 T2N1 (i)
14 Squamous cell T2N0 ITCs N1/micrometastases N2 T2N2
19 Squamous cell T2N1 Micrometastases N2 T2N2
27 Adeno T2N0 Micrometastases N1 T2N1
IHC, immunohistochemistry; ITCs, isolated tumor cells.
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et al.,14 patients with micrometastatic N2 disease seemed to
have the same poor outcome as patients with bulky N2
disease, although immunohistochemistry was not used to
detect these micrometastases. The authors suggest microme-
tastases to be the consequence of a more aggressive biologic
behavior, resulting in a worse outcome. Moreover, a relation-
ship of micrometastases with micropapillary adenocarcinoma
has been suggested previously.15
Rather than being a separate entity, micrometastases
and isolated tumor cells may also just represent an early
phase in the development of lymph node metastases and thus
being the result of a more accurate pathologic assessment.
This would be in line with a high prevalence of mediastinal
micrometastases in patients with overt N1 disease, as found
in our study.
The occurrence of any lymphatic dissemination may
well be the result of specific biologic features of a carcinoma
that can be different from one tumor to another. Detterbeck
et al.16 proposed four distinguished patterns of biologic be-
havior of lung cancer, with a separate propensity for local
invasion, lymphatic and hematogenous dissemination, and
multifocal spread in lung parenchyma. Patients with micro-
metastastic lymph node involvement without metastases at a
distant site seem to have at least a propensity for lymphatic
dissemination, detected in an early phase. Nevertheless, be-
cause all patients with lymphatic micrometastases in our
study had a first recurrence at a distant site, the propensity
for lymphatic dissemination seems to predict the propen-
sity for hematogenous dissemination as well, as has been
found by others.17
In our study in 10 patients with recurrent disease, no
lymphatic micrometastases were detected. Although some
lymphatic micrometastases may be missed, because we per-
formed immunohistochemistry on two additional slides of
each lymph node only, the propensity for hematogenous
dissemination was probably independent from lymphatic dis-
semination in these patients. Moreover, the time interval until
their first recurrence for these patients was not significantly
different from patients with lymphatic micrometastases, but
both groups are small and our study was not designed to find
a difference between these patient subsets.
If lymphatic micrometastases represent clinically im-
portant tumor dissemination, the question raises about the
optimal staging and treatment algorithm. When immunohis-
tochemistry is routinely applied in case of a cervical medi-
astinoscopy, the diagnostic yield is expected to increase,18
resulting in a new subset of patients with minimal mediastinal
involvement. Results of surgery as a first line treatment in
patients with preoperatively detected N2 involvement are
poor,19 so probably induction or even definitive chemoradio-
therapy will be offered to these patients.
On the other hand, mediastinal staging based on com-
puted tomography, FDG-PET, and eventually esophageal
ultrasound or endobronchial ultrasound-fine needle aspiration
is gaining interest with an expected lower yield of lymphatic
tissue,20 underestimating the incidence of micrometastases
and isolated tumor cells. After a subsequent resection, includ-
ing mediastinal lymph node dissection, the use of serial
sectioning and immunohistochemistry will then increase the
incidence of unexpected N2 involvement and hereby the
indication for adjuvant therapy. Which of these treatment
sequences is most optimal for this subset of patients with
microscopic N2 disease is unclear and has to be deter-
mined.
Routine use of serial sectioning and immunohistochem-
istry in lymph node assessment will add extra cost and time
to the pathology department, what may hamper general ap-
plication. However, the price of serial sectioning and immu-
nohistochemical staining at two levels in our study was only
$22.50 per lymph node and assessment took approximately 5
minutes extra. Because we examined an average of 4.5
mediastinal lymph node stations per patient, containing 2.4
lymph nodes, the extra cost with regard to the mediastinal
lymph nodes was $245.00 and approximately 1 hour of
time. In comparison, the price of FDG-PET in our institu-
tion is approximately $1700.00, and assessment also takes
half an hour.
Despite our results, confirmation in a large prospective
trial is desirable. Preferably, only patients without any lymph
node involvement at all after staining with hematoxylin and
eosin are included, so that micrometastases are the only kind
of dissemination.
In conclusion, the prevalence of lymphatic microme-
tastases detected by serial sectioning and immunohisto-
chemistry is higher in patients with NSCLC with recurrent
disease after a complete resection then in patients without
recurrent disease, thus, representing a kind of tumor dis-
semination with a clear impact on prognosis. We recom-
mend the routine use of serial sectioning and immunohis-
tochemistry in lymph node assessment of both lymphatic
tissue obtained by mediastinoscopy and after thoracotomy,
to improve the accuracy of staging. The optimal treatment for
patients with minimal mediastinal lymph node involvement
still has to be determined.
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